Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Tuesday, July 1, 2014
FDA Outlines Guidance and Rules for Compounding Drug Products
FDA has outlined its guidance and rules for the compounding of drug products by releasing policy documents as part of the agency’s effort to implement the compounding provisions of the Drug Quality and Security Act (DQSA), enacted in November 2013. The policy documents consist of a draft interim guidance, a proposed rule, a final guidance, and two revised requests for nominations for the bulk drug substances lists.
“Providing clarity to the compounding industry on the agency’s expectations for these unapproved drug products is a priority for the agency,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research, in a press release. “These actions are essential next steps in providing the compounding industry with the appropriate tools to comply with the law and advancing the FDA’s efforts to continue protecting patients.”
continue to read here
“Providing clarity to the compounding industry on the agency’s expectations for these unapproved drug products is a priority for the agency,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research, in a press release. “These actions are essential next steps in providing the compounding industry with the appropriate tools to comply with the law and advancing the FDA’s efforts to continue protecting patients.”
continue to read here
Member Feedback Requested on Proposed Sterile Compounding Regulations
June 30, 2014 BJ Bartleson, RN, MS, NEA-BC
The California State Board of Pharmacy has produced a new draft of proposed regulations for pharmacies that compound or compound sterile preparations. The changes will be considered by the board for release for a 45-day comment period during its July 30 meeting. Many of the proposed regulations affect facility and equipment standards for sterile compounding such as ventilation, negative pressure and ante rooms. It is especially important for small, rural and critical access hospitals to review the proposed regulations. In the interest of developing the best regulations, the Board of Pharmacy has granted CHA an opportunity to submit feedback on physical plant modifications by July 9.
CHA Medication Safety Committee leaders — and others who worked together to compose extensive comments to the board’s original language in January — are analyzing the new regulations and drafting comments. In addition, CHA will host an all-member call on July 8 for interested hospitals to gather information and participate in discussion of the Board of Pharmacy changes, as well as CHA’s comments and proposal.
CHA encourages all members to compare the proposed physical and plant structural changes to current compounding facility and equipment standards and submit comments to CHA on the attached proposed worksheet and/or participate in the July 8 call:
Tuesday, July 8
4 p.m. – 5 p.m.
(800) 882-3610, Passcode 5968133#
Attached are CHA’s Jan. 10 comment letter, the Board of Pharmacy proposed language and a worksheet for submitting comments.
CHA Medication Safety Committee leaders — and others who worked together to compose extensive comments to the board’s original language in January — are analyzing the new regulations and drafting comments. In addition, CHA will host an all-member call on July 8 for interested hospitals to gather information and participate in discussion of the Board of Pharmacy changes, as well as CHA’s comments and proposal.
CHA encourages all members to compare the proposed physical and plant structural changes to current compounding facility and equipment standards and submit comments to CHA on the attached proposed worksheet and/or participate in the July 8 call:
Tuesday, July 8
4 p.m. – 5 p.m.
(800) 882-3610, Passcode 5968133#
Attached are CHA’s Jan. 10 comment letter, the Board of Pharmacy proposed language and a worksheet for submitting comments.
Preparation is critical to high-risk sterile compounding; High-risk compounding should be a last resort to address drug shortages, said ASHP
July 01, 2014
Every year, FDA reports shortages of hundreds of drugs, the majority of which are sterile injectables. Currently, there are 251 drugs in shortage, 199 of which are sterile injectables, according to the American Society of Health-System Pharmacists (ASHP). These numbers are similar to those of the last 5 years, according to FDA.
In the face of drug shortages, health-system pharmacists often must perform high-risk sterile compounding, but this should be an emergency last resort, said Angela Yaniv, PharmD, Assistant Director of Pharmacy at Cleveland Clinic, at last year’s ASHP Midyear Clinical Meeting and Exhibition in Orlando, FL. Before undertaking high-risk compounding, pharmacists should ensure there is no other way to acquire the drugs. Once the procedure is deemed indispensable, pharmacists should evaluate the feasibility of the high-risk compounding procedure and take measures to ensure the products are well prepared.
In the face of drug shortages, health-system pharmacists often must perform high-risk sterile compounding, but this should be an emergency last resort, said Angela Yaniv, PharmD, Assistant Director of Pharmacy at Cleveland Clinic, at last year’s ASHP Midyear Clinical Meeting and Exhibition in Orlando, FL. Before undertaking high-risk compounding, pharmacists should ensure there is no other way to acquire the drugs. Once the procedure is deemed indispensable, pharmacists should evaluate the feasibility of the high-risk compounding procedure and take measures to ensure the products are well prepared.
Weigh your options
When a drug is in short supply, health-system pharmacists should consider the following before taking on high-risk compounding: (1) expected duration of shortage; (2) the health system’s current supply of the drug and potential for inventory management during the shortage; (3) possible alternative manufacturers or sizes available for aliquoting; (4) possible therapeutic substitutions for the drug and the need for Pharmacy and Therapeutics Committee approval; and (5) outsourcing compounding.Don't Get Burned By Sunshine: The Latest on the Physician Payments Sunshine Act
Don't Get Burned By Sunshine: The Latest on the Physician Payments Sunshine Act | ||||
Register for the latest CLE from the American Bar Association Health Law Section. | ||||
Don't Get Burned By Sunshine: The Latest on the Physician Payments Sunshine Act | ||||
Tuesday, July 15, 2014 | ||||
12:00 PM - 1:30 PM Eastern | ||||
1.5 CLE Requested | ||||
Webinar | ||||
This webinar will cover subjects such as:
| ||||
2 easy ways to learn more and register
|
FDA seeks permanent injunction against California pharmaceutical company
FDA seeks permanent injunction against California pharmaceutical company
For Immediate Release
July 1, 2014
Release
On June 25, the U.S. Department of Justice, at the request of the U.S. Food and Drug Administration, filed a complaint for permanent injunction in the U.S. District Court for the Central District of California against Laclede, Inc. (Laclede) of Rancho Dominguez, California, and its president, Michael A. Pellico. The complaint claims that Laclede illegally distributes over-the-counter vaginal drug products without required FDA approval.
According to the complaint, Laclede is in violation of the Federal Food, Drug, and Cosmetic Act for introducing unapproved and improperly labeled (misbranded) drugs for sale across the country. The prebiotic vaginal products named in the complaint are:
“The drug approval process is critical to ensuring that drugs are safe and effective for their intended uses,” said Carol Bennett, acting director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research. “The FDA will take swift action when companies bypass this important process established to protect consumers from harmful products.”
Since 2010, the FDA has repeatedly told the company that it must obtain the FDA’s approval before selling its drug products. According to the complaint, the company subsequently marketed and distributed the unapproved drug products, despite the FDA’s warnings.
The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
According to the complaint, Laclede is in violation of the Federal Food, Drug, and Cosmetic Act for introducing unapproved and improperly labeled (misbranded) drugs for sale across the country. The prebiotic vaginal products named in the complaint are:
- Luvena Prebiotic Vaginal Moisturizer and Lubricant
- Luvena Prebiotic Enhanced Personal Lubricant
- Luvena Prebiotic Feminine Wipes
- Luvena Prebiotic Daily Therapeutic Wash
“The drug approval process is critical to ensuring that drugs are safe and effective for their intended uses,” said Carol Bennett, acting director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research. “The FDA will take swift action when companies bypass this important process established to protect consumers from harmful products.”
Since 2010, the FDA has repeatedly told the company that it must obtain the FDA’s approval before selling its drug products. According to the complaint, the company subsequently marketed and distributed the unapproved drug products, despite the FDA’s warnings.
The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
HIGH IMPORTANCE!! MUST READ!!! FDA outlines expectations for human drug compounders, including registered outsourcing facilities
Today, the U.S. Food and Drug Administration issued several policy documents regarding compounded drug products for human use, as part of the agency’s continuing effort to implement the compounding provisions of the Drug Quality and Security Act (DQSA), enacted in November 2013. The policy documents consist of a draft interim guidance, a proposed rule, a final guidance, and two revised requests for nominations for the bulk drug substances lists.
“Providing clarity to the compounding industry on the agency’s expectations for these unapproved drug products is a priority for the agency,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “These actions are essential next steps in providing the compounding industry with the appropriate tools to comply with the law and advancing the FDA’s efforts to continue protecting patients.”
The documents available today are:
The draft interim guidance and proposed rule are available for public comment for 60 days, and the dockets are open for the public to nominate bulk drug substances for compounding under section 503A or 503B for 90 days.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
“Providing clarity to the compounding industry on the agency’s expectations for these unapproved drug products is a priority for the agency,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “These actions are essential next steps in providing the compounding industry with the appropriate tools to comply with the law and advancing the FDA’s efforts to continue protecting patients.”
The documents available today are:
- Draft interim guidance that describes the FDA’s expectations regarding compliance with current good manufacturing practice (CGMP) requirements for facilities that compound human drugs and register with the FDA as outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The guidance focuses on CGMP requirements related to sterility assurance of sterile drug products and the general safety of compounded drug products.
- A proposed rule that would revise the FDA’s current list of drug products that may not be compounded because the drug products have been withdrawn or removed from the market because they were found to be unsafe or not effective. The proposed rule would modify the description of one drug product on the list and add 25 drug products to the list.
The list set forth in the proposed rule would apply to both compounders and outsourcing facilities seeking to compound drugs for human use under sections 503A and 503B, respectively.
- Final guidance for individuals or pharmacies that intend to compound drugs under section 503A, now that the FD&C Act has been amended by the DQSA. The guidance generally restates the provisions of section 503A, describes the FDA’s interim policies with respect to specific provisions that require implementing regulations or other actions, and contains a non-exhaustive list of potential enforcement actions against individuals or pharmacies that compound human drug products in violation of the FD&C Act.
- Two Federal Register Notices stating the FDA is reopening the nomination process for two lists of bulk drug substances (active pharmaceutical ingredients) that may be used to compound drug products. One list is for drug products compounded in accordance with section 503A, and the other list is for drug products compounded in accordance with section 503B of the FD&C Act. In response to a December 2013 request for nominations, the agency received nominations that were not for bulk drug substances used in compounding, and that did not provide sufficient information to justify inclusion of the substances on the lists.
The draft interim guidance and proposed rule are available for public comment for 60 days, and the dockets are open for the public to nominate bulk drug substances for compounding under section 503A or 503B for 90 days.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
###
Inquiries
Subscribe to:
Posts (Atom)